CJC-1295: clinical evidence record
Also known as: CJC-1295 with DAC, CJC-1295 without DAC, Modified GRF (1-29)
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Independent, and paid nothing. We take no commission, no referral fee and no payment from any retailer, clinic or pharmacy on this site. Outbound links are ordinary untracked links. How we are funded.
AI-friendly summary · CJC-1295
Developed by ConjuChem Inc in the 2000s. Phase 1 and Phase 2 human safety and pharmacokinetic work was conducted before commercial development paused. Sustained GH and IGF-1 elevation observed with the DAC variant in published trial work.
Mechanism of action
How CJC-1295 works
30-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) variant uses a maleimidopropionic acid linker to covalently bind serum albumin, extending half-life from minutes to roughly 6 to 8 days in published preclinical and early-human work.
Top peer-reviewed citations
Selection of the most-cited peer-reviewed literature on CJC-1295. Where a verified PMID or DOI is shown, the citation links to the original record. Other citations list the title, authors, journal and year so the reader can locate the paper through the journal index or the PubMed search linked below. PeptideClear publishes editorial commentary, not clinical guidance.
-
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al.. The Journal of clinical endocrinology and metabolism, 2006.
-
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA. The Journal of clinical endocrinology and metabolism, 2006.
-
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Sackmann-Sala L, Berryman DE, Lubbers ER, List EO, Kopchick JJ. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009.
-
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Alba M, Fintini D, Sagazio A, et al.. American journal of physiology. Endocrinology and metabolism, 2006.
-
Advances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh S, Gavrilović I, Ng K, et al.. Drug testing and analysis, 2021.
-
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, DE Oliveira Neves LF, Camilo RP. The Journal of sports medicine and physical fitness, 2026.
-
Doping and sports endocrinology: growth hormone, IGF-1, insulin, and erythropoietin
García-Arnés JA, García-Casares N. Revista clinica espanola, 2023.
-
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
Timms M, Ganio K, Forbes G, et al.. Drug testing and analysis, 2019.
-
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Villegas Meza AD, Nocek M, Mitchell BC, et al.. JBJS reviews, 2026.
-
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L. International journal of molecular sciences, 2026.
-
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, Shypilova I, Bolgova O. Frontiers in aging, 2026.
-
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.), 2026.
-
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
-
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, et al.. The American journal of sports medicine, 2026.
Full PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+GHRH.
Registered clinical trials
As of 2026-07-13, CJC-1295 has 1 interventional trial listed on ClinicalTrials.gov and the ISRCTN registry. Registration means a study is planned, running or completed. It is not evidence of efficacy, and a listing is not an endorsement.
| Study | Phase | Status | Location | Registry |
|---|---|---|---|---|
| A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity NCT00267527 | Phase 2 | Terminated | Not stated | ClinicalTrials.gov |
Source: ClinicalTrials.gov and the ISRCTN registry, refreshed 2026-07-13. See the peptide clinical-trials tracker for the full picture across compounds.
UK regulatory status
Plain-English summary of where CJC-1295 sits under the four UK and international frameworks that govern peptide supply. Editorial commentary, not legal advice.
- Misuse of Drugs Act 1971: Not controlled under the Misuse of Drugs Act 1971.
- Psychoactive Substances Act 2016: Not scheduled under the Psychoactive Substances Act 2016.
- MHRA medicines classification: No UK marketing authorisation as a medicine.
- WADA Prohibited List: WADA Prohibited List S2 (peptide hormones, growth factors), prohibited at all times.
Full regulatory record: CJC-1295 UK regulatory status.
Risks and unknowns
What the literature does not yet show about CJC-1295
Known concerns
- The evidence for CJC-1295 is mixed: some human data exists alongside a larger preclinical literature. Mixed evidence is easy to quote selectively, so check whether a claim you have read rests on the human work or the animal work.
- 1 registered interventional trials exist for CJC-1295, none currently recruiting. Registered trials can be completed, suspended or terminated without ever publishing.
- CJC-1295 holds no UK marketing authorisation, so nothing you can buy has been assessed by a regulator, released by batch, or dispensed by an accountable pharmacy. Purity, dose accuracy and sterility rest entirely on the seller's own documentation.
- CJC-1295 appears on the WADA Prohibited List. For anyone subject to testing under UK Anti-Doping or an international federation, use is a violation, and detection windows for peptide metabolites extend well beyond the period of use.
Open questions in the literature
- Long-term outcomes beyond the duration of the published trials are unknown, and the published trials are considerably shorter than the periods over which people actually use these compounds.
- Interactions between CJC-1295 and prescribed medicines are not systematically studied, which matters most for anyone already on treatment for a long-term condition.
Regulatory note
No UK marketing authorisation as a medicine. Prohibited at all times under WADA S2 (peptide hormones, growth factors). The moment a UK seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Related reading on PeptideClear
Frequently asked questions
What is the evidence level for CJC-1295?
What is the UK regulatory status of CJC-1295?
Has CJC-1295 been tested in human clinical trials?
Where can I read the source literature for CJC-1295?
Last verified 2026-05-22. Editorial commentary, not legal or clinical advice. Citations without a linked identifier can be located through the PubMed search and the journal index.